DelveInsight’s “Plaque Psoriasis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Plaque Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Plaque Psoriasis Treatment Landscape @ https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight

Key Takeaways from the Plaque Psoriasis Pipeline Report

• On June 23, 2026- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. initiated a phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged ≥ 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.
• On June 16, 2026- Alumis Inc. conducted a study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.
• On June 18, 2026- Bristol-Myers Squibb conducted a phase 3 study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis.
• On June 17, 2026- Takeda announced a phase 3 study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis respond to it. The study will be done in 2 parts: Part A will include both children and teenagers, while part B will only include children.
• On 09 June 2026- Galderma R&D initiated a study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients. Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen’s efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.
• DelveInsight’s Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Plaque Psoriasis treatment.
• The leading Plaque Psoriasis Companies such as Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
• Promising Plaque Psoriasis Therapies such as EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.

Gain in-depth knowledge of key Plaque Psoriasis clinical trials, emerging drugs, and market opportunities @ Plaque Psoriasis Clinical Trials Assessment

The Plaque Psoriasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Plaque Psoriasis Pipeline Report also highlights the unmet needs with respect to the Plaque Psoriasis.

Plaque Psoriasis Overview

Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely. Plaque psoriasis typically presents with large oval-circular plaques over the scalp, trunk and extensor body surface. The plaques have an extensive amount of scaling due to the hyperproliferation of the epidermal cells. Most patients have acute flares and relapses of plaque psoriasis, which may sometimes become severe and progress into the pustular subtype.

Plaque Psoriasis Emerging Drugs Profile

• ARQ-151: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis.

• ABY-035: Affibody

ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.

• AK101: Akeso Biopharma

AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn’s disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson’s Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn’s disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat Plaque Psoriasis

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Plaque Psoriasis Unmet Needs

The Plaque Psoriasis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
• Plaque Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.

Plaque Psoriasis Companies

Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.

Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Plaque Psoriasis Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

See the latest progress in drug development and clinical research @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Plaque Psoriasis Pipeline Report

• Coverage- Global
• Plaque Psoriasis Companies:- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
• Plaque Psoriasis Therapies- EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
• Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Immunological and Autoimmune Disorders Research @ Plaque Psoriasis Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Plaque Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Plaque Psoriasis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. ARQ-151: Arcutis Biotherapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABY-035: Affibody
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CT303: GC Cell
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Plaque Psoriasis Key Companies
21. Plaque Psoriasis Key Products
22. Plaque Psoriasis- Unmet Needs
23. Plaque Psoriasis- Market Drivers and Barriers
24. Plaque Psoriasis- Future Perspectives and Conclusion
25. Plaque Psoriasis Analyst Views
26. Plaque Psoriasis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight